The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) formed a Task Force on the Application of Cardiac Bio-markers (TF-CB) in 2008, re-designated in 2018 as a committee (C-CB), to produce educational materials on cardiac biomarkers. Established in June 2017, definitive tables covering the majority of highsensitivity, contemporary and point-of-care (POC) cTn assays have been developed by the C-CB and are available on the IFCC website. These tables provide extensive information about assays' analytical characteristics and encompass information on diagnostic discriminants, particularly the 99th percentiles, as provided by the manufacturers.
The Global Task Force for Fourth Universal Definition of Myocardial Infarction (MI) utilizes cardiac troponin (cTn) as the standard biomarker for the detection of myocardial injury [1] . An increased cTn concentration above the upper reference limit (URL) defines myocardial injury, with cTn URLs specified as sex-specific 99th percentiles of a normal healthy reference population, defined by sex, age, racial and ethnic diversity [1] [2] [3] [4] . Prior to 2000, the definition of MI utilized a different diagnostic discriminant, the 97.5th percentile of a reference population, for a 'cardiac enzyme', typically total creatine kinase (CK) or its MB isoenzyme (CK-MB) [5] .
When first introduced into routine clinical practice, cTn assays were evaluated against the WHO diagnostic criteria for MI as the diagnostic gold standard. Using the WHO criteria as the diagnostic standard resulted in a relatively high diagnostic discriminant, typically 10-50 times the cTn 99th percentile. Shortly after, the redefinition of MI guidelines endorsed the preferred diagnostic discriminant as cTn, with a statement that cTn assays should ideally have a 10% coefficient of variation (CV) at the assay's 99th percentile URL concentration [6] . Assays were considered to be clinically acceptable if they had a %CV at the 99th percentile ≤20%, as patients would not be misclassified at this concentration [7] . Introduction of cTn assays into routine clinical use was accompanied by a range of different proposed diagnostic URLs for the diagnosis of MI, likely due to the misunderstanding of the intent and recommendations within the guidelines. Surveys of laboratory practice revealed that there was still use of a range of biomarkers other than cTn and a great deal of uncertainty as to what diagnostic URL (WHO equivalent, 10% or 20% CV concentration, or the 99th percentile) was appropriate [8] .
The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) formed a Task Force on the Application of Cardiac Bio-markers (TF-CB) in 2008, re-designated in 2018 as a committee (C-CB), to produce educational materials on cardiac biomarkers [3] [4] [5] . Since the 2007 survey [2] [3] [4] , there has been progressive improvement in assay analytical sensitivity, culminating in the development and global clinical implementation of high-sensitivity (hs) cTn assays [2] [3] [4] . Subsequent surveys, most recently in 2016, have shown that although there has been a shift to cTn as the LoB, limit of blank; LoD, limit of detection; NP, not provided; C, capture antibody; D, detection antibody; M, male; F, female; Conc, concentration; WW, worldwide; OUS, outside United States; n, number. All data have been listed as provided by the manufacturer, except Tosoh assay that was abstracted from package insert due to lack of correspondence from manufacturer. preferred and primary biomarker, there remains a lack of a consistent approach to the interpretation of cTn measurements [9] . Although the IFCC C-CB has defined the analytical characteristics to define 'high sensitivity', there also continues to be confusion as to what defines an hs-cTn assay and how to optimally use hs-cTn assays clinically.
The current environment is partly due to both the rapid pace in assay development and to the legacy of the varied range of diagnostic URLs for MI. The IFCC C-CB seeks to address the broader educational needs of the laboratory and clinical community and to provide authoritative, explanatory reference documents for global widespread use. The C-CB has academic, clinical and industry membership and works collaboratively with other clinical and laboratory medicine groups, such as the European Federation of Laboratory Medicine (EFLM) and the Academy of the American Association of Clinical Chemists (AACC). To date, several peer reviewed manuscripts have been produced to explain the concept of hs-cTn assays [2, 3] . The top eight analytical and top three clinical key components for the implementation of hs-cTn assays have been summarized as educational aids on a poster and a mouse pad and are currently available for distribution (poster) from by the IFCC if desired.
Established in June 2017, definitive tables covering the majority of high-sensitivity (Table 1) , contemporary ( Table 2 ) and point-of-care (POC) ( Table 3) cTn assays have been developed by the C-CB and are available on the IFCC website [10] [11] [12] . These tables provide extensive information about assays' analytical characteristics and encompass information on diagnostic discriminants, particularly the 99th percentiles, as provided by the manufacturers. In addition, a table that addresses the effects of hemolysis and biotin on cTn assays has been published [13] and posted to the IFCC website [14] . All tables will be updated on a quarterly basis. Further, tables summarizing analytical characteristics of natriuretic peptides (NP) [15] and effects of hemolysis and biotin on NP assays [16] are also found on the website. An educational document for NPs, paralleling the cTn document, is under development by the C-CB.
A series of industry sponsored workshops are being planned at major congresses, and started with the 2018 AACC annual meeting in Chicago. Most importantly, the C-CB wishes to encourage educational feedback from the laboratory and clinical communities on what they and their clinical colleagues find challenging in routine clinical use of cardiac biomarkers, specifically high sensitivity cTn assays. LoB, limit of blank; LoD, limit of detection; NP, not provided; C, capture antibody; D, detection antibody; M, male; F, female; Conc, concentration; WW, worldwide; n, number. All data have been listed as provided by the manufacturer, except Response Biomedical assay that was abstracted from package insert due to lack of correspondence from manufacturer. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
